[en] Osteoarthritis (OA) is the most common joint disease, affecting hundreds of millions of people globally, which leads to a high cost of treatment and further medical care and an apparent decrease in patient prognosis. The recent view of OA pathogenesis is that increased vascularity, bone remodeling, and disordered turnover are influenced by multivariate risk factors, such as age, obesity, and overloading. The view also reveals the gap between the development of these processes and early stage risk factors. This review presents the latest research on OA-related signaling pathways and analyzes the potential roles of perlecan, a typical component of the well-known protective structure against osteoarthritic pericellular matrix (PCM). Based on the experimental results observed in end-stage OA models, we summarized and analyzed the role of perlecan in the development of OA. In normal cartilage, it plays a protective role by maintaining the integrin of PCM and sequesters growth factors. Second, perlecan in cartilage is required to not only activate vascular epithelium growth factor receptor (VEGFR) signaling of endothelial cells for vascular invasion and catabolic autophagy, but also for different signaling pathways for the catabolic and anabolic actions of chondrocytes. Finally, perlecan may participate in pain sensitization pathways.
Disciplines :
Public health, health care sciences & services General & internal medicine
Author, co-author :
Zhao, Xiao-Xuan; Deparment of Orthopedics, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China, Xiangya School of Medicine, Central South University, Changsha 410083, Hunan, China
Xie, Wen-Qing; Deparment of Orthopedics, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
Xiao, Wen-Feng; Deparment of Orthopedics, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
Li, Heng-Zhen; Deparment of Orthopedics, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
Naranmandakh, Shinen; School of Arts and Sciences, National University of Mongolia, Sukhbaatar district, 14201 Ulaanbaatar, Mongolia
Bruyere, Olivier ; Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart Tilman B23, 4000 Liège, Belgium
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique
Li, Yu-Sheng; Deparment of Orthopedics, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China. Electronic address: liyusheng@csu.edu.cn
Language :
English
Title :
Perlecan: Roles in osteoarthritis and potential treating target.
Burr, D.B., Gallant, M.A., Bone remodelling in osteoarthritis. Nat. Rev. Rheumatol. 8:11 (2012), 665–673.
Liu, C., et al. Protective effects of the pericellular matrix of chondrocyte on articular cartilage against the development of osteoarthritis. Histol. Histopathol. 33:8 (2018), 757–764.
Gilbert, S.J., Bonnet, C.S., Blain, E.J., Mechanical cues: bidirectional reciprocity in the extracellular matrix drives mechano-signalling in articular cartilage. Int. J. Mol. Sci., 22(24), 2021.
Sibole, S.C., et al. The protective function of directed asymmetry in the pericellular matrix enveloping chondrocytes. Ann. Biomed. Eng. 50:1 (2022), 39–55.
Wilusz, R.E., Sanchez-Adams, J., Guilak, F., The structure and function of the pericellular matrix of articular cartilage. Matrix Biol. 39 (2014), 25–32.
Guilak, F., et al. Osteoarthritis as a disease of the cartilage pericellular matrix. Matrix Biol. 71–72 (2018), 40–50.
Chery, D.R., et al. Early changes in cartilage pericellular matrix micromechanobiology portend the onset of post-traumatic osteoarthritis. Acta Biomater. 111 (2020), 267–278.
Snow, A.D., et al. Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease. Arch. Biochem. Biophys. 320:1 (1995), 84–95.
Rescan, P.Y., et al. Distribution and origin of the basement membrane component perlecan in rat liver and primary hepatocyte culture. Am. J. Pathol. 142:1 (1993), 199–208.
Melrose, J., et al. The structure, location, and function of perlecan, a prominent pericellular proteoglycan of fetal, postnatal, and mature hyaline cartilages. J. Biol. Chem. 281:48 (2006), 36905–36914.
Melrose, J., Perlecan, a modular instructive proteoglycan with diverse functional properties. Int. J. Biochem. Cell Biol., 128, 2020, 105849.
Lin, P.Y., et al. A novel pathogenic HSPG2 mutation in schwartz-jampel syndrome. Front. Neurol., 12, 2021, 632336.
Gao, G., et al. Impact of perlecan, a core component of basement membrane, on regeneration of cartilaginous tissues. Acta Biomater. 135 (2021), 13–26.
Martinez, J.R., Dhawan, A., Farach-Carson, M.C., Modular proteoglycan Perlecan/HSPG2: mutations, phenotypes, and functions. Genes (Basel), 9(11), 2018.
Ishijima, M., et al. Perlecan modulates VEGF signaling and is essential for vascularization in endochondral bone formation. Matrix Biol. 31:4 (2012), 234–245.
Murdoch, A.D., et al. Primary structure of the human heparan sulfate proteoglycan from basement membrane (HSPG2/perlecan). A chimeric molecule with multiple domains homologous to the low density lipoprotein receptor, laminin, neural cell adhesion molecules, and epidermal growth factor. J. Biol. Chem. 267:12 (1992), 8544–8557.
Iozzo, R.V., Basement membrane proteoglycans: from cellar to ceiling. Nat. Rev. Mol. Cell Biol. 6:8 (2005), 646–656.
Bork, P., Patthy, L., The SEA module: a new extracellular domain associated with O-glycosylation. Protein Sci. 4:7 (1995), 1421–1425.
Brown, M.P., et al. Exercise and injury increase chondroitin sulfate chain length and decrease hyaluronan chain length in synovial fluid. Osteoarthr. Cartil. 15:11 (2007), 1318–1325.
Yang, W.D., et al. Perlecan domain I promotes fibroblast growth factor 2 delivery in collagen I fibril scaffolds. Tissue Eng. 11:1–2 (2005), 76–89.
Chuang, C.Y., et al. Heparan sulfate-dependent signaling of fibroblast growth factor 18 by chondrocyte-derived perlecan. Biochemistry 49:26 (2010), 5524–5532.
Xu, Y., Liu, Y.-J., Yu, Q., Angiopoietin-3 is tethered on the cell surface via heparan sulfate proteoglycans *. J. Biol. Chem. 279:39 (2004), 41179–41188.
Akerlund, M., et al. Laminin alpha1 domains LG4-5 are essential for the complete differentiation of visceral endoderm. Cell Tissue Res. 338:1 (2009), 129–137.
Bengtsson, E., et al. The leucine-rich repeat protein PRELP binds perlecan and collagens and may function as a basement membrane Anchor*. J. Biol. Chem. 277:17 (2002), 15061–15068.
Brown, J.C., et al. The C-terminal domain V of perlecan promotes β1 integrin-mediated cell adhesion, binds heparin, nidogen and Fibulin-2 and can be modified by glycosaminoglycans. Eur. J. Biochem. 250:1 (1997), 39–46.
Nishida, T., et al. CTGF/Hcs24, hypertrophic chondrocyte-specific gene product, interacts with perlecan in regulating the proliferation and differentiation of chondrocytes. J. Cell. Physiol. 196:2 (2003), 265–275.
Tiedemann, K., et al. Microfibrils at basement membrane zones interact with perlecan via fibrillin-1. J. Biol. Chem. 280:12 (2005), 11404–11412.
Smith, S.M., West, L.A., Hassell, J.R., The core protein of growth plate perlecan binds FGF-18 and alters its mitogenic effect on chondrocytes. Arch. Biochem. Biophys. 468:2 (2007), 244–251.
Hopf, M., et al. Recombinant domain IV of perlecan binds to nidogens, laminin-nidogen complex, fibronectin, fibulin-2 and heparin. Eur. J. Biochem. 259:3 (1999), 917–925.
Hopf, M., et al. Mapping of binding sites for nidogens, fibulin-2, fibronectin and heparin to different IG modules of perlecan. J. Mol. Biol. 311:3 (2001), 529–541.
Martinez, J.R., et al. Perlecan/HSPG2: signaling role of domain IV in chondrocyte clustering with implications for schwartz-jampel syndrome. J. Cell. Biochem. 120:2 (2019), 2138–2150.
Göhring, W., et al. Mapping of the binding of platelet-derived growth factor to distinct domains of the basement membrane proteins BM-40 and perlecan and distinction from the BM-40 collagen-binding epitope. Eur. J. Biochem. 255:1 (1998), 60–66.
Mongiat, M., et al. Perlecan protein core interacts with extracellular matrix protein 1 (ECM1), a glycoprotein involved in bone formation and angiogenesis. J. Biol. Chem. 278:19 (2003), 17491–17499.
Hayes, A.J., et al. Pericellular colocalisation and interactive properties of type VI collagen and perlecan in the intervertebral disc. Eur. Cell. Mater. 32 (2016), 40–57.
Smith, S.M., Melrose, J., Type XI collagen-perlecan-HS interactions stabilise the pericellular matrix of annulus fibrosus cells and chondrocytes providing matrix stabilisation and homeostasis. J. Mol. Histol. 50:3 (2019), 285–294.
Wilusz, R.E., Defrate, L.E., Guilak, F., A biomechanical role for perlecan in the pericellular matrix of articular cartilage. Matrix Biol. 31:6 (2012), 320–327.
Nakamura, R., Nakamura, F., Fukunaga, S., Disruption of endogenous perlecan function improves differentiation of rat articular chondrocytes in vitro. Anim. Sci. J. 86:4 (2015), 449–458.
Schätti, O.R., et al. Mechanical loading of cartilage explants with compression and sliding motion modulates gene expression of lubricin and catabolic enzymes. Cartilage 6:3 (2015), 185–193.
Ocken, A.R., et al. Perlecan knockdown significantly alters extracellular matrix composition and organization during cartilage development. Mol. Cell. Proteomics 19:7 (2020), 1220–1235.
Severmann, A.C., et al. An altered heparan sulfate structure in the articular cartilage protects against osteoarthritis. Osteoarthr. Cartil. 28:7 (2020), 977–987.
Shu, C.C., et al. Elevated hypertrophy, growth plate maturation, glycosaminoglycan deposition, and exostosis formation in the Hspg2 exon 3 null mouse intervertebral disc. Biochem. J. 476:2 (2019), 225–243.
Zcharia, E., et al. Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models. FASEB J. 19:2 (2005), 211–221.
Ellman, M.B., et al. Fibroblast growth factor control of cartilage homeostasis. J. Cell. Biochem. 114:4 (2013), 735–742.
Janssen, J.N., et al. The influence of TGF-β3, EGF, and BGN on SOX9 and RUNX2 expression in human chondrogenic progenitor cells. J. Histochem. Cytochem. 67:2 (2019), 117–127.
Weng, T., et al. Genetic inhibition of fibroblast growth factor receptor 1 in knee cartilage attenuates the degeneration of articular cartilage in adult mice. Arthritis Rheum. 64:12 (2012), 3982–3992.
Tan, Q., et al. A novel FGFR1-binding peptide attenuates the degeneration of articular cartilage in adult mice. Osteoarthr. Cartil. 26:12 (2018), 1733–1743.
Yan, D., et al. Fibroblast growth factor receptor 1 is principally responsible for fibroblast growth factor 2-induced catabolic activities in human articular chondrocytes. Arthritis Res. Ther., 13(4), 2011, R130.
Sun, C., et al. Selectivity in glycosaminoglycan binding dictates the distribution and diffusion of fibroblast growth factors in the pericellular matrix. Open Biol., 6(3), 2016.
Hodgkinson, T., et al. Mechanosignalling in cartilage: an emerging target for the treatment of osteoarthritis. Nat. Rev. Rheumatol. 18:2 (2022), 67–84.
Smith, S.M., et al. Heparan and chondroitin sulfate on growth plate perlecan mediate binding and delivery of FGF-2 to FGF receptors. Matrix Biol. 26:3 (2007), 175–184.
Zhao, Z., et al. Mechanotransduction pathways in the regulation of cartilage chondrocyte homoeostasis. J. Cell. Mol. Med. 24:10 (2020), 5408–5419.
Xie, Y., et al. Fibroblast growth factor signalling in osteoarthritis and cartilage repair. Nat. Rev. Rheumatol. 16:10 (2020), 547–564.
Tang, J., et al. Fibroblast growth factor receptor 3 inhibits osteoarthritis progression in the knee joints of adult mice. Arthritis Rheumatol. 68:10 (2016), 2432–2443.
Zhou, S., et al. Conditional deletion of Fgfr3 in chondrocytes leads to osteoarthritis-like defects in temporomandibular joint of adult mice. Sci. Rep., 6, 2016, 24039.
Woods, S., et al. miR-324-5p is up regulated in end-stage osteoarthritis and regulates indian hedgehog signalling by differing mechanisms in human and mouse. Matrix Biol. 77 (2019), 87–100.
Yao, X., et al. Fibroblast growth factor 18 exerts anti-osteoarthritic effects through PI3K-AKT signaling and mitochondrial fusion and fission. Pharmacol. Res. 139 (2019), 314–324.
Mori, Y., et al. Identification of fibroblast growth factor-18 as a molecule to protect adult articular cartilage by gene expression profiling. J. Biol. Chem. 289:14 (2014), 10192–10200.
Shu, C.C., et al. Ablation of perlecan domain 1 heparan sulfate reduces progressive cartilage degradation, synovitis, and osteophyte size in a preclinical model of posttraumatic osteoarthritis. Arthritis Rheumatol. 68:4 (2016), 868–879.
Sadatsuki, R., et al. Perlecan is required for the chondrogenic differentiation of synovial mesenchymal cells through regulation of Sox9 gene expression. J. Orthop. Res. 35:4 (2017), 837–846.
Hunger-Glaser, I., et al. PDGF and FGF induce focal adhesion kinase (FAK) phosphorylation at Ser-910: dissociation from Tyr-397 phosphorylation and requirement for ERK activation. J. Cell. Physiol. 200:2 (2004), 213–222.
Ohbayashi, N., et al. FGF18 is required for normal cell proliferation and differentiation during osteogenesis and chondrogenesis. Genes Dev. 16:7 (2002), 870–879.
Zoeller, J.J., Whitelock, J.M., Iozzo, R.V., Perlecan regulates developmental angiogenesis by modulating the VEGF-VEGFR2 axis. Matrix Biol. 28:5 (2009), 284–291.
Dong, Y., et al. VEGF promotes cartilage angiogenesis by phospho-ERK1/2 activation of Dll4 signaling in temporomandibular joint osteoarthritis caused by chronic sleep disturbance in wistar rats. Oncotarget 8:11 (2017), 17849–17861.
Chen, Y., et al. HIF-1-VEGF-notch mediates angiogenesis in temporomandibular joint osteoarthritis. Am. J. Transl. Res. 11:5 (2019), 2969–2982.
Pulsatelli, L., et al. New findings in osteoarthritis pathogenesis: therapeutic implications. Ther. Adv. Chronic Dis. 4:1 (2013), 23–43.
De Santis, M., et al. The role of wnt pathway in the pathogenesis of OA and its potential therapeutic implications in the field of regenerative medicine. Biomed. Res. Int., 2018, 2018, 7402947.
Lories, R.J., Monteagudo, S., Review article: is wnt signaling an attractive target for the treatment of osteoarthritis?. Rheumatol. Ther. 7:2 (2020), 259–270.
Xiao, W.F., et al. Functional role of hedgehog pathway in osteoarthritis. Cell Biochem. Funct. 38:2 (2020), 122–129.
Ai, X., et al. QSulf1 remodels the 6-O sulfation states of cell surface heparan sulfate proteoglycans to promote wnt signaling. J. Cell Biol. 162:2 (2003), 341–351.
Matsuo, I., Kimura-Yoshida, C., Extracellular distribution of diffusible growth factors controlled by heparan sulfate proteoglycans during mammalian embryogenesis. Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci., 369(1657), 2014.
Duan, R., Xie, H., Liu, Z.Z., The role of autophagy in osteoarthritis. Front. Cell Dev. Biol., 8, 2020, 608388.
Musumeci, G., et al. Biomarkers of chondrocyte apoptosis and autophagy in osteoarthritis. Int. J. Mol. Sci. 16:9 (2015), 20560–20575.
Wang, S., et al. The role of autophagy and mitophagy in bone metabolic disorders. Int. J. Biol. Sci. 16:14 (2020), 2675–2691.
Qin, N., et al. Local intra-articular injection of resveratrol delays cartilage degeneration in C57BL/6 mice by inducing autophagy via AMPK/mTOR pathway. J. Pharmacol. Sci. 134:3 (2017), 166–174.
Takayama, K., et al. Local intra-articular injection of rapamycin delays articular cartilage degeneration in a murine model of osteoarthritis. Arthritis Res. Ther., 16(6), 2014, 482.
Ribeiro, M., et al. Diabetes-accelerated experimental osteoarthritis is prevented by autophagy activation. Osteoarthr. Cartil. 24:12 (2016), 2116–2125.
Caramés, B., et al. Autophagy activation by rapamycin reduces severity of experimental osteoarthritis. Ann. Rheum. Dis. 71:4 (2012), 575–581.
Caramés, B., et al. The relationship of autophagy defects to cartilage damage during joint aging in a mouse model. Arthritis Rheumatol. 67:6 (2015), 1568–1576.
Ning, L., et al. Perlecan inhibits autophagy to maintain muscle homeostasis in mouse soleus muscle. Matrix Biol. 48 (2015), 26–35.
Neill, T., et al. A functional outside-in signaling network of proteoglycans and matrix molecules regulating autophagy. Matrix Biol. 100–101 (2021), 118–149.
Chen, C.G., Iozzo, R.V., Extracellular matrix guidance of autophagy: a mechanism regulating cancer growth. Open Biol., 12(1), 2022, 210304.
Manton, K.J., et al. Disruption of heparan and chondroitin sulfate signaling enhances mesenchymal stem cell-derived osteogenic differentiation via bone morphogenetic protein signaling pathways. Stem Cells 25:11 (2007), 2845–2854.
Usher, K.M., et al. Pathological mechanisms and therapeutic outlooks for arthrofibrosis. Bone Res., 7, 2019, 9.
Li, B., et al. Pathological mechanism of chondrocytes and the surrounding environment during osteoarthritis of temporomandibular joint. J. Cell. Mol. Med. 25:11 (2021), 4902–4911.
Roemer, F.W., et al. Presence of MRI-detected joint effusion and synovitis increases the risk of cartilage loss in knees without osteoarthritis at 30-month follow-up: the MOST study. Ann. Rheum. Dis. 70:10 (2011), 1804–1809.
Liu-Bryan, R., Terkeltaub, R., Emerging regulators of the inflammatory process in osteoarthritis. Nat. Rev. Rheumatol. 11:1 (2015), 35–44.
van Caam, A., et al. Perlecan expression is strongly reduced in aging cartilage but increased by physiological loading. Osteoarthr. Cartil., 22, 2014, S60.
Caramés, B., et al. Autophagy is a protective mechanism in normal cartilage, and its aging-related loss is linked with cell death and osteoarthritis. Arthritis Rheum. 62:3 (2010), 791–801.
Vincent, T.L., et al. Basic fibroblast growth factor mediates transduction of mechanical signals when articular cartilage is loaded. Arthritis Rheum. 50:2 (2004), 526–533.
Goldring, M.B., Otero, M., Inflammation in osteoarthritis. Curr. Opin. Rheumatol. 23:5 (2011), 471–478.
Sacitharan, P.K., Ageing and osteoarthritis. Subcell. Biochem. 91 (2019), 123–159.
Grindel, B.J., et al. Matrilysin/MMP-7 cleavage of Perlecan/HSPG2 complexed with semaphorin 3A supports FAK-mediated stromal invasion by prostate cancer cells. Sci. Rep., 8(1), 2018, 7262.
Sahin, H., Trautwein, C., Wasmuth, H.E., Functional role of chemokines in liver disease models. Nat. Rev. Gastroenterol. Hepatol. 7:12 (2010), 682–690.
Saikia, P., et al. Basement membranes in the cornea and other organs that commonly develop fibrosis. Cell Tissue Res. 374:3 (2018), 439–453.
Kaneko, H., et al. Synovial perlecan is required for osteophyte formation in knee osteoarthritis. Matrix Biol. 32:3–4 (2013), 178–187.
Madej, W., et al. Ageing is associated with reduction of mechanically-induced activation of Smad2/3P signaling in articular cartilage. Osteoarthr. Cartil. 24:1 (2016), 146–157.
Chanalaris, A., et al. Heparan sulfate proteoglycan synthesis is dysregulated in human osteoarthritic cartilage. Am. J. Pathol. 189:3 (2019), 632–647.
Zhang, W., et al. Current research on pharmacologic and regenerative therapies for osteoarthritis. Bone Res., 4, 2016, 15040.
Lord, M.S., et al. The multifaceted roles of perlecan in fibrosis. Matrix Biol. 68–69 (2018), 150–166.
Hayes, A.J., Whitelock, J., Melrose, J., Regulation of FGF-2, FGF-18 and transcription factor activity by perlecan in the maturational development of transitional rudiment and growth plate cartilages and in the maintenance of permanent cartilage homeostasis. Int. J. Mol. Sci., 23(4), 2022.
Behonick, D.J., et al. Role of matrix metalloproteinase 13 in both endochondral and intramembranous ossification during skeletal regeneration. PLoS One, 2(11), 2007, e1150.
Usmani, S.E., et al. Transforming growth factor alpha controls the transition from hypertrophic cartilage to bone during endochondral bone growth. Bone 51:1 (2012), 131–141.
Garcia, J., et al. Perlecan in the natural and cell therapy repair of human adult articular cartilage: can modifications in this proteoglycan be a novel therapeutic approach?. Biomolecules, 11(1), 2021.
Deyle, G.D., et al. Effectiveness of manual physical therapy and exercise in osteoarthritis of the knee. A randomized, controlled trial. Ann. Intern. Med. 132:3 (2000), 173–181.
Goh, S.L., et al. Efficacy and potential determinants of exercise therapy in knee and hip osteoarthritis: a systematic review and meta-analysis. Ann. Phys. Rehabil. Med. 62:5 (2019), 356–365.
Vincent, K.R., et al. Eccentric and concentric resistance exercise comparison for knee osteoarthritis. Med. Sci. Sports Exerc. 51:10 (2019), 1977–1986.
French, H.P., Abbott, J.H., Galvin, R., Adjunctive therapies in addition to land-based exercise therapy for osteoarthritis of the hip or knee. Cochrane Database Syst. Rev., 10(10), 2022, Cd011915.
Gay, C., Educating patients about the benefits of physical activity and exercise for their hip and knee osteoarthritis. Systematic literature review. Ann. Phys. Rehabil. Med. 59:3 (2016), 174–183.
Hayes, A.J., Melrose, J., Electro-stimulation, a promising therapeutic treatment modality for tissue repair: emerging roles of sulfated glycosaminoglycans as electro-regulatory mediators of intrinsic repair processes. Adv. Ther., 3(11), 2020, 2000151.
Ahsin, S., et al. Clinical and endocrinological changes after electro-acupuncture treatment in patients with osteoarthritis of the knee. Pain 147:1–3 (2009), 60–66.
Chen, N., et al. Electro-acupuncture is beneficial for knee osteoarthritis: the evidence from meta-analysis of randomized controlled trials. Am. J. Chin. Med. 45:5 (2017), 965–985.
Jha, A.K., et al. Perlecan domain I-conjugated, hyaluronic acid-based hydrogel particles for enhanced chondrogenic differentiation via BMP-2 release. Biomaterials 30:36 (2009), 6964–6975.
Nagai, T., et al. Bevacizumab, an anti-vascular endothelial growth factor antibody, inhibits osteoarthritis. Arthritis Res. Ther., 16(5), 2014, 427.
Lee, S., Nemeño, J.G., Lee, J.I., Repositioning bevacizumab: a promising therapeutic strategy for cartilage regeneration. Tissue Eng. B Rev. 22:5 (2016), 341–357.
Smith, M.M., Hayes, A.J., Melrose, J., Pentosan polysulphate (PPS), a semi-synthetic heparinoid DMOAD with roles in intervertebral disc repair biology emulating the stem cell instructive and tissue reparative properties of heparan sulphate. Stem Cells Dev. 31:15–16 (2022), 406–430.
Zhang, M., et al. Advanced application of stimuli-responsive drug delivery system for inflammatory arthritis treatment. Mater. Today Bio, 14, 2022, 100223.
Hochberg, M.C., et al. Effect of intra-articular sprifermin vs placebo on femorotibial joint cartilage thickness in patients with osteoarthritis: the FORWARD randomized clinical trial. JAMA 322:14 (2019), 1360–1370.
Eckstein, F., et al. Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study. Ann. Rheum. Dis. 80:8 (2021), 1062–1069.
Eckstein, F., et al. Intra-articular sprifermin reduces cartilage loss in addition to increasing cartilage gain independent of location in the femorotibial joint: post-hoc analysis of a randomised, placebo-controlled phase II clinical trial. Ann. Rheum. Dis. 79:4 (2020), 525–528.
Auw Yang, K.G., et al. Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial. Osteoarthr. Cartil. 16:4 (2008), 498–505.
Kerkhof, H.J., et al. Large-scale meta-analysis of interleukin-1 beta and interleukin-1 receptor antagonist polymorphisms on risk of radiographic hip and knee osteoarthritis and severity of knee osteoarthritis. Osteoarthr. Cartil. 19:3 (2011), 265–271.
Schnitzer, T.J., et al. Effect of tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis among patients with osteoarthritis of the hip or knee: a randomized clinical trial. JAMA 322:1 (2019), 37–48.
Malemud, C.J., Inhibition of MMPs and ADAM/ADAMTS. Biochem. Pharmacol. 165 (2019), 33–40.
Zhang, W., et al. Emerging trend in the pharmacotherapy of osteoarthritis. Front. Endocrinol., 10, 2019, 431.
Hayes, A.J., Melrose, J., Glycosaminoglycan and proteoglycan biotherapeutics in articular cartilage protection and repair strategies: novel approaches to visco-supplementation in orthobiologics. Adv. Ther., 2(8), 2019, 1900034.
Zhu, X., et al. Effectiveness and safety of glucosamine and chondroitin for the treatment of osteoarthritis: a meta-analysis of randomized controlled trials. J. Orthop. Surg. Res., 13(1), 2018, 170.
Hochberg, M.C., et al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann. Rheum. Dis. 75:1 (2016), 37–44.
Arden, N.K., et al. Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines. Nat. Rev. Rheumatol. 17:1 (2021), 59–66.
Burt, P.M., et al. Ablation of low-molecular-weight FGF2 isoform accelerates murine osteoarthritis while loss of high-molecular-weight FGF2 isoforms offers protection. J. Cell. Physiol. 234:4 (2019), 4418–4431.
